Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

U.S. Hospitals Urge DOJ Antitrust Probe of Anthem-Cigna Deal

Caroline Humer  |  August 7, 2015

NEW YORK (Reuters)—U.S. hospitals urged antitrust regulators this week to consider whether health insurer Anthem Inc’s planned acquisition of rival Cigna Corp would boost healthcare costs.

In a letter to the Department of Justice, the hospital industry’s largest lobbying group said combining the No. 1 and No. 5 health insurers threatens to reduce competition in 817 geographic markets serving 45 million consumers.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In many of those markets, the American Hospital Association said, there are no strong competitors to buy assets that Anthem or Cigna might want to sell to pass muster with federal authorities. State insurance regulators will also look at the deal.

A Cigna spokesman did not have an immediate comment. An Anthem spokeswoman also did not have an immediate comment.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

On July 24, Anthem announced plans to buy Cigna for $47 billion, the second major insurance deal announced this summer. Aetna Inc on July 3 inked an agreement with Humana Inc. The deals will reduce the number of national insurers to three from five.

Anthem and Cigna have said they expect the deal to pass antitrust scrutiny and they have considered where asset sales might be needed.

The hospital association said in the letter dated Aug. 5 that it doubted Anthem and Cigna would find a suitable buyer for assets that provide insurance plans to millions of customers, also known as covered lives. Merging companies often will sell assets to a competitor if they believe it will help a larger deal pass regulatory scrutiny.

“In the 817 at-risk markets, over half the lives that need to be divested reside across 368 (metro regions) and rural counties with no divestiture possibility,” the group wrote.

Anthem and Cigna may need to divest from 2.9 million to 3.7 million covered lives in the commercial business to preserve competition in those markets, it said, and 1.7 million to 2 million of those are in markets with no potential acquirer. The analysis was based on the Herfindahl-Hirschman Index that measures market concentration.

In the commercial self-funded insurance business, where employers pay Anthem and Cigna to manage benefits, 4.4 million to 4.7 million covered lives may need to be sold, and there is no satisfactory acquirer for 2.8 million to 3 million lives, the letter said.

The hospitals also urged the DOJ to look at the reduced competition in the market for national customers, citing the Federal Trade Commission case against Sysco Corp., which the FTC ultimately won.

Page: 1 2 | Single Page
Share: 

Filed under:Facility Tagged with:Department of JusticeHealth Insurancehospital

Related Articles

    U.S. Court Blocks Anthem-Cigna Deal

    February 9, 2017

    (Reuters)—A federal judge on Wednesday ruled against U.S. health insurer Anthem Inc.’s proposed $54 billion merger with smaller rival Cigna Corp, derailing an unprecedented effort to consolidate the country’s health insurance industry. The U.S. Department of Justice sued in July to stop Anthem’s purchase of Cigna, a deal that would have created the largest U.S….

    Beware Antitrust Laws When Considering Healthcare Mergers

    March 1, 2015

    Analysis of laws governing collaboration of healthcare systems, hospitals and physician practices should be done before consolidating

    Anthem to Buy Cigna to Create Biggest U.S. Health Insurer

    July 24, 2015

    (Reuters)—Anthem Inc. said on Friday it would buy Cigna Corp. in a deal valued at $54.2 billion, creating the largest U.S. health insurer by membership. The deal—the biggest ever in the health insurance industry—comes three weeks after Aetna Inc agreed to buy Humana Inc for $37 billion and is part of an industry-wide consolidation following…

    Doubts Mount over Merger of Health Insurers Anthem, Cigna

    May 24, 2016

    (Reuters)—Wall Street expressed growing doubts about a pending $54 billion merger of U.S. health insurers Anthem Inc. and Cigna Corp. on Monday as news of management squabbles added to concerns over its review by antitrust regulators. Cigna shares closed down 4% at $126.15, well below Anthem’s original $188 per share offer of cash and stock…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences